Carbogen (95% Oxygen, 5% Carbon Dioxide) Inhalation in Cancer Treatment
Carbogen is a mixture of 95% oxygen and 5% carbon dioxide and is inhaled as an adjunct to treatment for various oncologic applications. Tumors are generally hypoxic in nature and researchers theorize that increasing the tumor oxygenation during administration of treatments, such as radiotherapy or chemotherapy, make the tumor more susceptible to the therapy being administered.
Carbogen is also called Meduna's Mixture after its inventor Ladislas Meduna. Meduna's original formula was 30% CO2 and 70% oxygen.
Carbogen inhalation as an adjunct for the treatment of cancer is considered investigational.
Any specific products referenced in this policy are just examples and are intended for illustrative purposes only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available. These examples are contained in the parenthetical e.g. statement.
We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits, or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the Medical Policy and a health plan, the express terms of the health plan will govern.
Controlled studies continue to be lacking in published literature that would help validate the application of carbogen inhalation as an adjunct for the treatment of cancer.
Alonzi, R., Padhani, A. R., Maxwell, R. J., Taylor, N. J., Stirling, J. J., Wilson, J. I., et al. (2009). Carbogen breathing increases prostate cancer oxygenation: A translational MRI study in murine xenografts and humans. British Journal of Cancer, 100 (4), 644-648. (Level 4 evidence)
Carpenter, C. M., Rakow-Penner, R., Jiang, S., Daniel, B. L., Poque, B. W., Glover, G. H., et al. (2010). Inspired gas-induced vascular change in tumors with magnetic-resonance-guided near-infrared imaging: Human breast pilot study. Journal of Biomedical Optics, 15 (3), 036026-1-036026-5. (Level 4 evidence)
Rademakers, S., Hoogsteen, I., Rijken, P., Terhaard, C., Doornaert, P., Langendijk, j. et. al. (2015, February) Prognostic value of the proliferation marker Ki-67 in laryngeal carcinoma: results of the accelerated radiotherapy with carbogen breathing and nicotinamide phase III randomized trial. Head and Neck; 37(2):171-6. Abstract retrieved January 31, 2017 from PubMed database.
Yip, K., & Alonzi, R. (2013). Carbogen gas and radiotherapy outcomes in prostate cancer. Therapeutic Advances in Urology, 5 (1), 25-34. (Level 4 evidence)
ORIGINAL EFFECTIVE DATE: 4/1/2001
MOST RECENT REVIEW DATE: 2/14/2019
Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.
This document has been classified as public information.